Objective To assess the efficacy of Rh-endostatin plus the combination of gemcitabine/navelbine and cisplatin in patients with non-small cell lung cancer (NSCLC).Methods NSCLC patients,not receiving chemotherapy,were divided into two groups.Then they were given the combination of gemcitabine/navelbine and cisplatin with or without Rh-endostatin at 2-week intervals for 4 treatment cycles.Results Forty patients were enrolled and all of them were assessable for response and toxicity.None had complete response but 4 patients had partial response.An overall response rate was 10%.The survival rate was 65% at 1 year,with a median survival time of 16.2 months.Hematological complications were the most common toxic reactions,with grade≥3 reactions occurring at rates of 7%,7%,4% and 2%,respectively.Conclusion Rh-endostatin may have anti-tumor activity with high clinical benefit rate and is well tolerated in lung cancer with stage Ⅲb/Ⅳ.Compared with single combination of gemcitabine/navelbine and cisplatin,no more significant unexpected adverse events were observed. Objective To assess the efficacy of Rh-endostatin plus the combination of gemcitabine / navelbine and cisplatin in patients with non-small cell lung cancer (NSCLC). Methods NSCLC patients, not receiving chemotherapy, were divided into two groups. They were given the combination of gemcitabine / navelbine and cisplatin with or without Rh-endostatin at 2-week intervals for 4 treatment cycles. Results Forty patients were enrolled and all of them were assessable for response and toxicity. None had complete response but 4 patients had partial response. An overall response rate was 10%. The survival rate was 65% at 1 year, with a median survival time of 16.2 months. Hematological complications were the most common toxic reactions, with grade ≧ 3 reactions occurring at rates of 7%, 7% , 4% and 2%, respectively.Conclusion Rh-endostatin may have anti-tumor activity with high clinical benefit rate and is well tolerated in lung cancer with stage IIIb / IV. Compared with single combination of gemcitabine / navelbin e and cisplatin, no more significant unexpected adverse events were observed.